Bezpieczeństwo kardiologiczne naproksenu u pacjenta z dną moczanową Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2020
Słowa kluczowe:
hiperurykemia, kolchicyna, NLPZ, rekomendacje, układ sercowo-naczyniowy
##plugins.themes.bootstrap3.article.main##
Abstrakt
Hiperurykemia uważana jest obecnie za chorobę metaboliczną, a częstość jej występowania stale rośnie. W efekcie współczesne społeczeństwa doświadczają ryzyka rozwoju spowodowanego zależnymi od hiperurykemii chorobami, włączając w to choroby układu sercowo-naczyniowego i dnę. Chociaż dnę rozpoznajemy od ponad 50 wieków, do jej leczenia wciąż stosujemy odkrytą ponad 200 lat temu kolchicynę czy niesteroidowe leki przeciwzapalne oraz glikokortykosteroidy, znane od ponad 70 lat. Jasną stroną pozostaje to, że leki te są wciąż skuteczne i stanowią I linię leczenia. Podstawowym pytaniem pozostaje natomiast, który z dostępnych leków powinienem być uznany za lek pierwszego wyboru. Wśród wielu NLPZ stosowanych w dnie naproksen wykazał znaczną skuteczność oraz wysoki profil bezpieczeństwa w leczeniu zapalenia i uśmierzaniu bólu, co uzasadnia jego użycie jako leku pierwszego wyboru w leczeniu dny.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Kotyla , P., & Postuła , M. (2020). Bezpieczeństwo kardiologiczne naproksenu u pacjenta z dną moczanową. Medycyna Faktów , 13(1(46), 60-64. https://doi.org/10.24292/01.MF.0120.6
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Zhu Y., Pandya B.J., Choi H.K.: Prevalence of gout and hyperuricemia in the us general population: The national health and nutrition examination survey 2007-2008. Arthritis Rheum. 2011; 63: 3136-3141.
2. Kuo C.F., Grainge M.J., Zhang W. et al.: Global epidemiology of gout: Prevalence, incidence and risk factors. Nat. Rev. Rheumatol. 2015; 11: 649-662.
3. Maślińska M., Raciborski F., Filipiak A. et al.: Występowanie i leczenie dny moczanowej w Polsce. Analiza, wskazania, rekomendacje 2015.
4. Qaseem A., Harris R.P., Forciea M.A.; Physicians, f.t.C.G.C.o.t.A.C.o. Management of acute and recurrent gout: A clinical practice guideline from the american college of physicians. Ann. Intern. Med. 2017; 166: 58-68.
5. Khanna D., Fitzgerald J.D., Khanna P.P. et al.: 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012; 64: 1431-1446.
6. Richette P., Doherty M., Pascual E. et al.: 2016 updated eular evidence-based recommendations for the management of gout. Ann. Rheum. Dis. 2017; 76: 29-42.
7. Wechalekar M.D., Vinik O., Moi J.H. et al.: The efficacy and safety of treatments for acute gout: Results from a series of systematic literature reviews including cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors. J. Rheumatol. Suppl. 2014; 92: 15-25.
8. Qaseem A., Harris R.P., Forciea M.A.: Management of acute and recurrent gout: A clinical practice guideline from the american college of physicians. Ann. Intern. Med. 2017; 166: 58-68.
9. Shekelle P.G., Newberry S.J., FitzGerald J.D. et al.: Management of gout: A systematic review in support of an american college of physicians clinical practice guideline. Ann. Intern. Med. 2017; 166: 37-51.
10. Zhang W., Doherty M., Bardin T. et al.: Eular evidence based recommendations for gout. Part ii: Management. Report of a task force of the eular standing committee for international clinical studies including therapeutics (escisit). Ann. Rheum. Dis. 2006; 65: 1312-1324.
11. Combe B., Swergold G., McLay J. et al.: Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (the medal study). Rheumatology (Oxford) 2009; 48: 425-432.
12. Zhang S., Zhang Y., Liu P. et al.: Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: A systematic review and a meta-analysis. Clin. Rheumatol. 2016; 35: 151-158.
13. Feng X., Tian M., Zhang W. et al.: Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One 2018; 13: e0190798.
14. Baraf H.S., Fuentealba C., Greenwald M. et al.: Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: Results of the etoricoxib versus diclofenac sodium gastrointestinal tolerability and effectiveness (edge) trial. J. Rheumatol. 2007; 34: 408-420.
15. DeArmond B., Francisco C.A., Lin J.S. et al.: Safety profile of over-the-counter naproxen sodium. Clin. Ther. 1995; 17: 587-601; discussion 586.
16. Janssens H.J., Janssen M., van de Lisdonk E.H. et al.: Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial. Lancet. 2008; 371: 1854-1860.
17. Roddy E., Clarkson K., Blagojevic-Bucknall M. et al.: Open-label randomised pragmatic trial (contact) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Ann. Rheum. Dis. 2020; 79: 276-284.
18. Borghi C., Rosei E.A., Bardin T. et al.: Serum uric acid and the risk of cardiovascular and renal disease. J. Hypertens. 2015; 33: 1729-1741.
19. Kanbay M., Segal M., Afsar B. et al.: The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013; 99: 759-766. DOI:10.1136/heartjnl-2012-302535.
20. Feig D.I., Soletsky B., Johnson R.J.: Effect of allopurinol on blood pressure of adoles-cents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008; 300: 924-932. DOI: 10.1001/jama.300.8.924.
21. Soletsky B., Feig D.I.: Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 2012; 60: 1148-1156. DOI: 10.1161/HYPERTENSIONAHA.112.196980.
22. Tuttle K.R., Short R.A., Johnson R.J.: Sex differences in uric acid and risk factors for coronary artery disease. Am. J. Cardiol. 2001; 87: 1411-1414.
23. Crouse J.R., Toole J.F., McKinney W.M. et al.: Risk factors for extracranial carotidartery atherosclerosis. Stroke. 1987; 18: 990-996.
24. Nieto F.J., Iribarren C., Gross M.D. et al.: Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000; 148: 131-139.
25. Iribarren C., Folsom A.R., Eckfeldt J.H. et al.: Correlates of 25. uric acid andits association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis risk in communities. Ann. Epidemiol. 1996; 6: 331-340.
26. Goodman and Gilman (red.): The pharmacological basis of therapeutics anti-inflammatory, antipyretic, and analgesic agents; Pharmacotherapy of Gout. 12th ed. Pergamon Press, New York 2011.
27. Maxwell S.R., Payne R.A., Murray G.D. et al.: Selectivity of NSAIDs for COX-2 and cardiovascular outcome. Br. J. Clin. Pharmacol. 2006; 62(2): 243-245.
28. Garcia-Rodriguez L.A., Tacconelli S., Patrignani P.: Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol. 2008; 52: 1628-1636.
29. Houston M.C., Weir M., Gray J. et al.: The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch. Intern. Med. 1995; 155(10): 1049-1054.
30. Moore R.A., Derry S., McQuay H.J.: Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet. Disord. 2007; 8: 73.
31. Furey S.A., Vargas R., McMahon F.G.: Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment. Pharmacotherapy. 1993; 13(2): 143-148.
32. Sowers J.R., White W.B., Pitt B. et al.: Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure: results of a randomized double blind controlled trial in treated hypertensive patients with osteoarthritis (OA) and type 2 diabetes mellitus. Am. J. Hypertens. 2003; 16(S1): OR-25.
33. Maxwell S.R., Payne R.A., Murray G.D. et al.: Selectivity of NSAIDs for COX-2 and cardiovascular outcome. Br. J. Clin. Pharmacol. 2006; 62(2): 243-245.
34. Coxib and traditional NSAID Trialists’ (CNT) Collaboration: Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382(9894): 769-779.
35. Nissen S.E., Yeomans N.D., Solomon D.H. et al.: Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. PRECISION Trial Investigators. N. Engl. J. Med. 2016; 375(26): 2519-2529.
36. Ruschitzka F., Borer J.S., Krum H. et al.: Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur. Heart J. 2017; 38(44): 3282-3292.
37. Bhatt D.L., Scheiman J., Abraham N.S. et al.: ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation task force on clinical expert consensus documents. J. Am. Coll. Cardiol. 2008; 52: 1502-1507.
2. Kuo C.F., Grainge M.J., Zhang W. et al.: Global epidemiology of gout: Prevalence, incidence and risk factors. Nat. Rev. Rheumatol. 2015; 11: 649-662.
3. Maślińska M., Raciborski F., Filipiak A. et al.: Występowanie i leczenie dny moczanowej w Polsce. Analiza, wskazania, rekomendacje 2015.
4. Qaseem A., Harris R.P., Forciea M.A.; Physicians, f.t.C.G.C.o.t.A.C.o. Management of acute and recurrent gout: A clinical practice guideline from the american college of physicians. Ann. Intern. Med. 2017; 166: 58-68.
5. Khanna D., Fitzgerald J.D., Khanna P.P. et al.: 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012; 64: 1431-1446.
6. Richette P., Doherty M., Pascual E. et al.: 2016 updated eular evidence-based recommendations for the management of gout. Ann. Rheum. Dis. 2017; 76: 29-42.
7. Wechalekar M.D., Vinik O., Moi J.H. et al.: The efficacy and safety of treatments for acute gout: Results from a series of systematic literature reviews including cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors. J. Rheumatol. Suppl. 2014; 92: 15-25.
8. Qaseem A., Harris R.P., Forciea M.A.: Management of acute and recurrent gout: A clinical practice guideline from the american college of physicians. Ann. Intern. Med. 2017; 166: 58-68.
9. Shekelle P.G., Newberry S.J., FitzGerald J.D. et al.: Management of gout: A systematic review in support of an american college of physicians clinical practice guideline. Ann. Intern. Med. 2017; 166: 37-51.
10. Zhang W., Doherty M., Bardin T. et al.: Eular evidence based recommendations for gout. Part ii: Management. Report of a task force of the eular standing committee for international clinical studies including therapeutics (escisit). Ann. Rheum. Dis. 2006; 65: 1312-1324.
11. Combe B., Swergold G., McLay J. et al.: Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (the medal study). Rheumatology (Oxford) 2009; 48: 425-432.
12. Zhang S., Zhang Y., Liu P. et al.: Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: A systematic review and a meta-analysis. Clin. Rheumatol. 2016; 35: 151-158.
13. Feng X., Tian M., Zhang W. et al.: Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One 2018; 13: e0190798.
14. Baraf H.S., Fuentealba C., Greenwald M. et al.: Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: Results of the etoricoxib versus diclofenac sodium gastrointestinal tolerability and effectiveness (edge) trial. J. Rheumatol. 2007; 34: 408-420.
15. DeArmond B., Francisco C.A., Lin J.S. et al.: Safety profile of over-the-counter naproxen sodium. Clin. Ther. 1995; 17: 587-601; discussion 586.
16. Janssens H.J., Janssen M., van de Lisdonk E.H. et al.: Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial. Lancet. 2008; 371: 1854-1860.
17. Roddy E., Clarkson K., Blagojevic-Bucknall M. et al.: Open-label randomised pragmatic trial (contact) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Ann. Rheum. Dis. 2020; 79: 276-284.
18. Borghi C., Rosei E.A., Bardin T. et al.: Serum uric acid and the risk of cardiovascular and renal disease. J. Hypertens. 2015; 33: 1729-1741.
19. Kanbay M., Segal M., Afsar B. et al.: The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013; 99: 759-766. DOI:10.1136/heartjnl-2012-302535.
20. Feig D.I., Soletsky B., Johnson R.J.: Effect of allopurinol on blood pressure of adoles-cents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008; 300: 924-932. DOI: 10.1001/jama.300.8.924.
21. Soletsky B., Feig D.I.: Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 2012; 60: 1148-1156. DOI: 10.1161/HYPERTENSIONAHA.112.196980.
22. Tuttle K.R., Short R.A., Johnson R.J.: Sex differences in uric acid and risk factors for coronary artery disease. Am. J. Cardiol. 2001; 87: 1411-1414.
23. Crouse J.R., Toole J.F., McKinney W.M. et al.: Risk factors for extracranial carotidartery atherosclerosis. Stroke. 1987; 18: 990-996.
24. Nieto F.J., Iribarren C., Gross M.D. et al.: Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000; 148: 131-139.
25. Iribarren C., Folsom A.R., Eckfeldt J.H. et al.: Correlates of 25. uric acid andits association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis risk in communities. Ann. Epidemiol. 1996; 6: 331-340.
26. Goodman and Gilman (red.): The pharmacological basis of therapeutics anti-inflammatory, antipyretic, and analgesic agents; Pharmacotherapy of Gout. 12th ed. Pergamon Press, New York 2011.
27. Maxwell S.R., Payne R.A., Murray G.D. et al.: Selectivity of NSAIDs for COX-2 and cardiovascular outcome. Br. J. Clin. Pharmacol. 2006; 62(2): 243-245.
28. Garcia-Rodriguez L.A., Tacconelli S., Patrignani P.: Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol. 2008; 52: 1628-1636.
29. Houston M.C., Weir M., Gray J. et al.: The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch. Intern. Med. 1995; 155(10): 1049-1054.
30. Moore R.A., Derry S., McQuay H.J.: Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet. Disord. 2007; 8: 73.
31. Furey S.A., Vargas R., McMahon F.G.: Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment. Pharmacotherapy. 1993; 13(2): 143-148.
32. Sowers J.R., White W.B., Pitt B. et al.: Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure: results of a randomized double blind controlled trial in treated hypertensive patients with osteoarthritis (OA) and type 2 diabetes mellitus. Am. J. Hypertens. 2003; 16(S1): OR-25.
33. Maxwell S.R., Payne R.A., Murray G.D. et al.: Selectivity of NSAIDs for COX-2 and cardiovascular outcome. Br. J. Clin. Pharmacol. 2006; 62(2): 243-245.
34. Coxib and traditional NSAID Trialists’ (CNT) Collaboration: Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382(9894): 769-779.
35. Nissen S.E., Yeomans N.D., Solomon D.H. et al.: Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. PRECISION Trial Investigators. N. Engl. J. Med. 2016; 375(26): 2519-2529.
36. Ruschitzka F., Borer J.S., Krum H. et al.: Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur. Heart J. 2017; 38(44): 3282-3292.
37. Bhatt D.L., Scheiman J., Abraham N.S. et al.: ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation task force on clinical expert consensus documents. J. Am. Coll. Cardiol. 2008; 52: 1502-1507.